Personal Statement
Aditi joined the University of Liverpool in August 2026 as a Senior Lecturer in ISMIB. She previously completed her dual masters in Biotechnology and Bioinformatics from University of Pune in India and trained in biophysical chemistry during her doctoral studies at University of Cambridge, UK with Professor Michele Vendruscolo and Professor Sir Chris Dobson for development of both theoretical and experimental approaches for studying RNA structure, dynamics and interactions. She was awarded the Sir Henry Wellcome Postdoctoral Fellowship to investigate the structure of a transcriptional activator complex in HIV with Professor Matthias Geyer (Bonn, Germany) and Professor Tom Steitz (Yale, USA) using X-ray Crystallography and Cryo-Electron Microscopy. In 2019, she started her group as a tenure-track Anne McLaren Fellow at University of Nottingham, UK and transitioned to a tenured academic position in 2023.

Research Overview
Aditi's research focusses on high-resolution studies of RNA-mediated disease pathologies in viral infection, rare genetic disorders and antimicrobial resistance. Her team uses an integration of experimental, computational and theoretical approaches encompassing mass spectrometry, molecular simulations and electron microscopy with molecular, cell and viral biology. Aditi recently pioneered cryogenic OrbiSIMS mass spectrometry guided modelling of native RNA structures in solution and in situ, which enabled the team to determine complete remodelling of a native human RNP on HIV infection and that of the HIV 5'UTR between different stages of the viral infection. Currently, Aditi's team is expanding on this toolkit by cryo-correlating with electron microscopy and tomography and orthogonal integration with optical tweezers and atomic force microscopy to study mechanism of neurovirulence in flaviviruses, attenuation in arenavirus, structural role of pathogenic RNA in phase separation during rare genetic disorders, mechanism of antimicrobial resistance and stability of mRNA cargo in therapeutic formulations and room-temperature supply chains.